| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1734-1140(13)71516-0 |
| P698 | PubMed publication ID | 24553003 |
| P50 | author | Elżbieta Lorenc-Koci | Q59690847 |
| Krystyna Ossowska | Q60477212 | ||
| P2860 | cites work | A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group | Q64955097 |
| Intellectual changes in patients with MPTP-induced parkinsonism | Q69872502 | ||
| Depressive symptoms in Parkinson's disease | Q80915141 | ||
| Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease | Q82531361 | ||
| Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study | Q83139326 | ||
| Stages in the development of Parkinson's disease-related pathology | Q29615834 | ||
| Memory, mood, dopamine, and serotonin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury | Q30470435 | ||
| The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease | Q33607256 | ||
| Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity | Q33617472 | ||
| Exercise effects on motor and affective behavior and catecholamine neurochemistry in the MPTP-lesioned mouse | Q33987540 | ||
| Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study | Q34038382 | ||
| Increased risk of Parkinson's disease after depression: a retrospective cohort study | Q34130645 | ||
| Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system | Q34395267 | ||
| Treatment options for depression and psychosis in Parkinson's disease | Q34430395 | ||
| Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women | Q34474458 | ||
| Depression in Parkinson's disease -- a review | Q34478301 | ||
| Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
| Spared caudal brainstem SERT binding in early Parkinson's disease | Q34724279 | ||
| Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. | Q34801837 | ||
| Psychiatric aspects of Parkinson's disease--an update | Q35838935 | ||
| Depression in Parkinson's disease: conceptual issues and clinical challenges | Q35863400 | ||
| Molecular pathophysiology of Parkinson's disease | Q36196507 | ||
| Animal models of the non-motor features of Parkinson's disease | Q36235578 | ||
| Molecular pathogenesis of Parkinson's disease | Q36242701 | ||
| Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats | Q36243814 | ||
| Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. | Q36738260 | ||
| Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias | Q37260948 | ||
| Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway | Q37543216 | ||
| Dopamine receptor agonists and depression in Parkinson's disease | Q37685695 | ||
| Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment | Q37771075 | ||
| The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future | Q37796015 | ||
| Treatment of depressive symptoms in Parkinson's disease | Q37831398 | ||
| The serotonergic system in Parkinson's disease | Q37924025 | ||
| Prodromal non-motor symptoms of Parkinson's disease. | Q40247459 | ||
| Biochemical aspects of Parkinson's disease | Q42460123 | ||
| Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. | Q42477740 | ||
| Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats | Q42502496 | ||
| Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. | Q42633181 | ||
| Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures | Q42794711 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine | Q43024089 | ||
| Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease | Q43185554 | ||
| Intraaccumbens dopaminergic lesion suppresses desipramine effects in the forced swim test but not in the neuronal activity of lateral septal nucleus | Q44551781 | ||
| Positron emission tomography of striatal serotonin transporters in Parkinson disease | Q44585433 | ||
| Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease. | Q46346508 | ||
| Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model | Q46706492 | ||
| Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter | Q48121057 | ||
| The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease | Q48147372 | ||
| Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process? | Q48443502 | ||
| Effect of antidepressant drugs on 6-OHDA-treated mice in the FST. | Q48508281 | ||
| MPTP-induced hippocampal effects on serotonin, dopamine, neurotrophins, adult neurogenesis and depression-like behavior are partially influenced by fluoxetine in adult mice. | Q48558309 | ||
| Mood changes and "on-off" phenomena in Parkinson's disease. | Q51170704 | ||
| Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. | Q51978130 | ||
| Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease--a [123 I]-ADAM SPECT study. | Q52899952 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 1545-1557 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Pharmacological Reports | Q15766499 |
| P1476 | title | Depression in Parkinson's disease | |
| P478 | volume | 65 |
| Q36124822 | Decrease of gene expression of astrocytic 5-HT2B receptors parallels development of depressive phenotype in a mouse model of Parkinson's disease |
| Q88991176 | Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease |
| Q30433136 | Essential tremor: a neurodegenerative disease? |
| Q38189542 | New trends in the neurobiology and pharmacology of affective disorders |
| Q34574771 | Psychiatric aspects of Parkinson's disease |
| Q26800109 | Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson's Disease: A Systematic Review |
Search more.